IBRX News

IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The Firm - IBRX

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Pomerantz LLP Shares Class Action Details With Shareholders in ImmunityBio, Inc. – IBRX

IBRX SHAREHOLDER RIGHTS ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 Ready to Announce with Confidence?

IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Concealed Drug Limitation Risks: Levi & Korsinsky

IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class Action - Contact Lieff Cabraser

IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!